161 related articles for article (PubMed ID: 14597963)
1. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.
Ho PC; Abbott FS; Zanger UM; Chang TK
Pharmacogenomics J; 2003; 3(6):335-42. PubMed ID: 14597963
[TBL] [Abstract][Full Text] [Related]
2. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
3. Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype.
Numa AM; Abbott FS; Chang TK
Can J Physiol Pharmacol; 2007 Sep; 85(9):848-55. PubMed ID: 18066130
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.
Amini-Shirazi N; Ghahremani MH; Ahmadkhaniha R; Mandegary A; Dadgar A; Abdollahi M; Shadnia S; Pakdaman H; Kebriaeezadeh A
Toxicol Mech Methods; 2010 Oct; 20(8):452-7. PubMed ID: 20602621
[TBL] [Abstract][Full Text] [Related]
5. P450-catalyzed in-chain desaturation of valproic acid: isoform selectivity and mechanism of formation of Delta 3-valproic acid generated by baculovirus-expressed CYP3A1.
Fisher MB; Thompson SJ; Ribeiro V; Lechner MC; Rettie AE
Arch Biochem Biophys; 1998 Aug; 356(1):63-70. PubMed ID: 9681992
[TBL] [Abstract][Full Text] [Related]
6. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
7. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.
Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K
Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614
[TBL] [Abstract][Full Text] [Related]
8. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
9. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
10. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE
J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
Kassahun K; Baillie TA
Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
[TBL] [Abstract][Full Text] [Related]
12. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
13. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.
Guo Y; Zhang Y; Wang Y; Chen X; Si D; Zhong D; Fawcett JP; Zhou H
Drug Metab Dispos; 2005 Jun; 33(6):749-53. PubMed ID: 15764711
[TBL] [Abstract][Full Text] [Related]
14. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].
Li J; Wen SY; Wang R; Chen K; Fang Y; Pei F; Wang SQ
Yao Xue Xue Bao; 2005 Aug; 40(8):695-9. PubMed ID: 16268502
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes.
Surendradoss J; Chang TK; Abbott FS
Toxicol Appl Pharmacol; 2012 Nov; 264(3):413-22. PubMed ID: 22940460
[TBL] [Abstract][Full Text] [Related]
16. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.
Visser LE; van Schaik RH; Jan Danser AH; Hofman A; Witteman JC; van Duijn CM; Uitterlinden AG; Pols HA; Stricker BH
Pharmacogenet Genomics; 2007 Jul; 17(7):473-9. PubMed ID: 17558303
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
18. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.
Sandberg M; Yasar U; Strömberg P; Höög JO; Eliasson E
Br J Clin Pharmacol; 2002 Oct; 54(4):423-9. PubMed ID: 12392591
[TBL] [Abstract][Full Text] [Related]
19. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
20. The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes.
Zhou Q; Matsumoto S; Ding LR; Fischer NE; Inaba T
Life Sci; 2004 Sep; 75(18):2145-55. PubMed ID: 15325841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
